Drugs / Inactivated H5N1 Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01258062 | Sep 2010 → Apr 2011 | — | Alachua Government Services, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated H5N1 Influenza Vaccine | “30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder” NCT01258062 ↗ |
| Known as | GelVac nasal powder H5N1 influenza vaccine. | “This is a double-blind, placebo controlled, safety and immunogenicity study of GelVac™ nasal powder H5N1 influenza vaccine.” NCT01258062 ↗ |
| Modality | Vaccine | “H5N1 influenza vaccine” NCT01258062 ↗ |
| Route | Intranasal | “given as two doses of 15 μg in one nostril” NCT01258062 ↗ |